Michael A. Savin

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy et al. · Journal of Clinical Oncology · 2009 · 586 citations

Medicine, Oncology, Pharmacology +11

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Stephen E. Jones, Michael A. Savin, Frankie A. Holmes et al. · Journal of Clinical Oncology · 2006 · 540 citations · Full text

Medicine, Oncology, Pharmacology +17

Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer

Frankie A. Holmes, Joyce O’Shaughnessy, S. Vukelja et al. · Journal of Clinical Oncology · 2002 · 517 citations

Medicine, Oncology, Pharmacology +17

Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer

Stephen G. Swisher, Jack A. Roth, John Nemunaitis et al. · JNCI Journal of the National Cancer Institute · 1999 · 497 citations · Full text

Medicine, Oncology, Pharmacology +14

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

Harpreet Wasan, Navesh Sharma, Volker Heinemann et al. · The Lancet Oncology · 2017 · 398 citations · Full text

Medicine, Oncology, Radiation Oncology +17